Saskatchewan Pharmacy Law JE Practice Exam (Sample)

Study Guide

Everything you need from our exam experts!

Questions

1. Which of the following is NOT a brand name included in Part I of the Schedule in Part G of the FDR?

A. Lisdexamfetamine (Vyvanse)

B. Methylphenidate (Biphentin)

C. Phenobarbital (Phenobarb)

D. Dextroamphetamine (Dexedrine)

2. What is the regulation concerning refills on prescriptions for monitored drugs?

A. Unlimited refills allowed

B. No refills permitted

C. Refills permitted with a follow-up consultation

D. Refills permitted up to three times

3. FDA Schedule A restricts the advertising of which type of treatments?

A. Prescription Drugs

B. Controlled Substances

C. Non-prescription Drugs

D. Diseases and Disorders

4. True or false: Refills for benzodiazepines require keeping a record for each refill.

A. True

B. False

C. Only if specified

D. Not applicable

5. What is required for the use or disclosure of personal information aside from meeting its initial purpose?

A. Consent from the individual

B. Notification from a third party

C. Written contract

D. Public approval

6. In nasal preparations for adult use and in ophthalmic products, what is their schedule?

A. Unscheduled

B. Schedule 1

C. Schedule 2

D. Schedule 3

7. Dextromethorphan and its salts are classified as Schedule __ except in oral dosage forms with specific package sizes.

A. Schedule 2

B. Unscheduled

C. Schedule 3

D. Schedule 1

8. All pharmacy operation records, such as fridge temperature logs, must be kept for a minimum of which period?

A. 1 year

B. 2 years

C. 5 years

D. 10 years

9. What concept in pharmacy ethics emphasizes providing benefit to a patient?

A. Nonmaleficence

B. Justice

C. Beneficence

D. Autonomy

10. What does the acronym ISAIDNO represent in pharmacy practice?

A. Informed consent and adequate documentation

B. Individual competence and sufficient information

C. Information sharing and adherence to regulations

D. Integration of services and individual needs

Answers

1. C
2. B
3. D
4. A
5. A
6. A
7. C
8. B
9. C
10. B

Explanations

1. Which of the following is NOT a brand name included in Part I of the Schedule in Part G of the FDR?

A. Lisdexamfetamine (Vyvanse)

B. Methylphenidate (Biphentin)

C. Phenobarbital (Phenobarb)

D. Dextroamphetamine (Dexedrine)

In the context of Saskatchewan Pharmacy Law and the Federal Drug Regulations (FDR), it's essential to understand how drugs are categorized and the significance of brand names versus generic names. Part I of the Schedule in Part G of the FDR lists specific controlled and regulated substances, often accompanied by their brand names. Lisdexamfetamine is marketed as Vyvanse and falls under controlled substances commonly used for ADHD. Methylphenidate, known as Biphentin, is also listed due to its use in treating ADHD. Dextroamphetamine, marketed as Dexedrine, is another stimulant included in the same category. However, Phenobarbital, the active ingredient in Phenobarb, is primarily classified as a barbiturate used for seizure management and does not fall into the stimulant category or the same regulations as the other options listed. It may have a different schedule or regulatory classification, which is why it is indicated as not being included in the same group as the others concerning the FDR's Part I Schedule. This understanding of both the classifications of these drugs and their regulations highlights why Phenobarbital (Phenobarb), despite being a recognized medication, does not belong in that particular part of the Schedule related to stimulants or controlled

2. What is the regulation concerning refills on prescriptions for monitored drugs?

A. Unlimited refills allowed

B. No refills permitted

C. Refills permitted with a follow-up consultation

D. Refills permitted up to three times

The regulation concerning refills on prescriptions for monitored drugs typically states that no refills are permitted. Monitored drugs are under strict regulation due to their potential for abuse and misuse. This regulatory framework is established to ensure patient safety, reduce the risk of addiction, and maintain strict control over substances that may have serious health implications. In this context, the prohibition on refills for monitored drugs ensures that each prescription is carefully assessed through a new consultation, allowing healthcare providers to evaluate the patient's current condition, medication effectiveness, and any potential harmful effects or contraindications since the last prescription was filled. This practice promotes responsible prescribing and aligns with public health objectives aimed at mitigating risks associated with controlled substances. While there may be specific guidelines that allow for varying refill policies on other types of medications, the stringent limitations on monitored drugs reflect an overall commitment to minimizing the risks associated with their use.

3. FDA Schedule A restricts the advertising of which type of treatments?

A. Prescription Drugs

B. Controlled Substances

C. Non-prescription Drugs

D. Diseases and Disorders

FDA Schedule A specifically restricts the advertising of treatments related to diseases and disorders. This regulation aims to ensure that the information provided to the public is accurate and not misleading, particularly when addressing serious health conditions. It prohibits advertising that may create a false sense of security or suggest guaranteed outcomes from treatments for conditions that can be complex or require a healthcare professional's guidance. By focusing on diseases and disorders, the regulation seeks to protect the public from potentially harmful claims and to encourage individuals to seek proper medical advice rather than relying solely on advertisements for treatment solutions. This emphasizes the importance of professional oversight in managing health conditions rather than self-diagnosis or treatment based solely on promotional material.

4. True or false: Refills for benzodiazepines require keeping a record for each refill.

A. True

B. False

C. Only if specified

D. Not applicable

Refills for benzodiazepines require keeping a separate record for each refill due to the controlled nature of these medications. Benzodiazepines are classified as Schedule IV controlled substances under Saskatchewan pharmacy regulations. As such, strict record-keeping is essential to monitor their prescribing and dispensing, to prevent misuse, and to ensure patient safety. Maintaining a record for each refill enables pharmacists and other healthcare providers to track the patient's medication use closely, helping to identify patterns that may indicate substance misuse or dependency. This requirement supports the overall goal of safeguarding public health while allowing patients who truly need these medications to access them responsibly. Keeping thorough records in this context is not just beneficial; it is a regulatory obligation, ensuring compliance with provincial and federal laws regarding controlled substances.

5. What is required for the use or disclosure of personal information aside from meeting its initial purpose?

A. Consent from the individual

B. Notification from a third party

C. Written contract

D. Public approval

The requirement for the use or disclosure of personal information aside from meeting its initial purpose is indeed based on the necessity of obtaining consent from the individual. This principle is embedded within privacy legislation and regulations that govern the handling of personal data. In the context of Saskatchewan pharmacy law, consent ensures that individuals have control over their own information and that it is used in ways they agree to. The requirement for consent illustrates the ethical and legal need to respect an individual's autonomy and privacy rights before any additional use or sharing of their personal information occurs. This understanding aligns with the importance of building trust between patients and healthcare providers, as consent fosters transparency in how personal health information is managed. Without obtaining proper consent, any further use or disclosure of personal information could potentially lead to legal repercussions and erode the trust necessary for effective healthcare delivery.

6. In nasal preparations for adult use and in ophthalmic products, what is their schedule?

A. Unscheduled

B. Schedule 1

C. Schedule 2

D. Schedule 3

Nasal preparations for adult use and ophthalmic products generally fall under the classification of unscheduled products, meaning they can be sold without a prescription and are accessible for consumer purchase in various settings, including retail pharmacies and stores. This classification is often due to their low potential for misuse and their low risk when used as directed for common conditions, such as allergies or eye irritation. As there are no significant restrictions on their sale, these products allow consumers to self-manage certain health issues effectively. In contrast, Schedule 1, Schedule 2, and Schedule 3 products typically involve more stringent regulations, requiring a pharmacist's intervention or prescription due to considerations like safety, potential for dependency, or the need for professional guidance in their use.

7. Dextromethorphan and its salts are classified as Schedule __ except in oral dosage forms with specific package sizes.

A. Schedule 2

B. Unscheduled

C. Schedule 3

D. Schedule 1

Dextromethorphan and its salts are classified as Schedule 3 substances, which is important for understanding their regulation and sale in Saskatchewan. Schedule 3 substances can be sold by retail pharmacies without a prescription, but certain conditions exist regarding their sale to prevent misuse and to ensure safety for consumers. Specifically, while dextromethorphan is allowed to be sold in those packages, it must adhere to restrictions based on the specific oral dosage forms and package sizes established in local regulations. This classification reflects a balance between accessibility for consumers who may need cough suppression and the necessity of monitoring potential abuse of the substance, often seen in larger quantities. Understanding this schedule is crucial for pharmacy practice, as it informs pharmacists about their responsibilities concerning the sale and distribution of these medications.

8. All pharmacy operation records, such as fridge temperature logs, must be kept for a minimum of which period?

A. 1 year

B. 2 years

C. 5 years

D. 10 years

In Saskatchewan, all pharmacy operation records, including refrigerator temperature logs, are required to be maintained for a minimum of two years. This duration is established to ensure that pharmacies can adequately track and verify the storage conditions of medications and related supplies, which is critical for patient safety and regulatory compliance. Maintaining these records for at least two years allows for the monitoring of any variations that could affect the efficacy of medications due to temperature fluctuations, ensuring that pharmacists can provide appropriate care and advice to patients based on the integrity of their medications. This retention period strikes a balance between effective management of documentation and the practicalities of resource conserving in the pharmacy setting.

9. What concept in pharmacy ethics emphasizes providing benefit to a patient?

A. Nonmaleficence

B. Justice

C. Beneficence

D. Autonomy

Beneficence is the ethical concept that focuses on actions that promote the well-being and benefit of patients. In pharmacy practice, this principle requires healthcare providers to actively contribute to the health and welfare of their patients by ensuring that the treatment provided is advantageous and leads to positive outcomes. This includes selecting effective medications, counseling patients on proper use, and considering the overall therapeutic regimen for improving health. By emphasizing beneficence, pharmacy professionals are guided to act in the best interest of their patients, making it a fundamental component of patient-centered care. This principle represents a commitment to providing not just any treatment, but the most beneficial treatment, thereby enhancing patients' health and quality of life.

10. What does the acronym ISAIDNO represent in pharmacy practice?

A. Informed consent and adequate documentation

B. Individual competence and sufficient information

C. Information sharing and adherence to regulations

D. Integration of services and individual needs

The acronym ISAIDNO represents essential principles in pharmacy practice, emphasizing the importance of both individual competence and sufficient information. This means that healthcare professionals must not only possess the necessary skills and knowledge to provide effective care but also ensure they have ample information to make informed decisions regarding patient treatment. This is particularly critical in pharmacy, where the accuracy of medication dispensing and patient counseling relies heavily on the pharmacist's competence and the availability of relevant information about medications, patient history, and treatment protocols. Being informed about a patient's condition, understanding the medication prescribed, and being competent in pharmacy practices are key to ensuring patient safety and optimizing therapeutic outcomes. Therefore, this interpretation aligns closely with the fundamental responsibilities of pharmacists and their role in patient care.